Comment on “Drug survival, effectiveness, and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years”

This letter comments on the recent study by Mastorino et al. reporting high long-term drug survival (87.2%) and effectiveness of risankizumab in real-world psoriasis treatment. We highlight a key methodological limitation—the lack of adherence assessment—which may confound interpretation of persistence outcomes. Incorporating adherence data in future studies would enhance the accuracy, interpretability, and clinical relevance of real-world evidence.